Dovonex Psoriasis Ointment has been reclassified from POM to P, the MHRA announced today (August 17).

Containing the vitamin D analogue calcipotriol 50mcg/g, it is indicated for treating mild to moderate plaque psoriasis that has been previously diagnosed by a doctor in adults aged 18 years and over. The treatment is for application once daily, with a maximum duration of use of 12 weeks and a maximum pack size of 60g.

Dr Sarah Branch, MHRA’s deputy director of vigilance and risk management of medicines, said: “Psoriasis is a chronic disease, which can have a major impact on people’s quality of life. By making this medicine more widely available, patients will be able to treat flare ups quickly without the need for a prescription.”

The RPS welcomed the news. President Ash Soni commented: “Widening access to medicine is great news for patients. Pharmacists are already able to sell products for the treatment of psoriasis with appropriate advice on management, application and side effects. We welcome the addition of Dovonex Psoriasis Ointment to the range of products available.”

Widening access to medicine is great news for patients

Recommended

Pharmacy research bursaries awarded

The recipients of the 2017 Health Education Foundation awards have been announced, including a project looking at pharm...

Pharmacist pioneers acknowledged in NE London

A project involving community pharmacists in Barking and Dagenham has won a Healthcare Pioneers Award

Popular

Building a nutritional foundation

This NPA-accredited module looks into the nutritional options available during an infant's first 1,000 days for mothers ...

Nutritional management of preterm infants

This NPA-accredited module looks into advising parents of preterm infants on their baby's unique nutritional needs to he...

Infant feeding and allergy risk

This NPA-accredited module highlights a clinically-proven hydrolysed formula that reduces the risk of developing allergi...